Abstract
There is only 1 US Food and Drug Administration-approved drug for acute ischemic stroke: tissue plasminogen activator (tPA). Due to a short time window and fear of intracerebral hemorrhage (ICH), tPA remains underutilized. There is great interest in developing combination drugs to use with tPA to improve the odds of a favorable recovery and to reduce the risk of ICH. Minocycline is a broad-spectrum antibiotic that has been found to be a neuroprotective agent in preclinical ischemic stroke models. Minocycline inhibits matrix metalloproteinase-9, a biomarker for ICH associated with tPA use. Minocycline is also an anti-inflammatory agent and inhibits poly (ADP-ribose) polymerase-1. Minocycline has been safe and well tolerated in the clinical trials conducted to date.
Original language | English (US) |
---|---|
Pages (from-to) | S7-S13 |
Journal | Reviews in Neurological Diseases |
Volume | 7 |
Issue number | SUPPL. 1 |
DOIs | |
State | Published - 2010 |
Keywords
- Acute ischemic stroke
- MMP-9
- Minocycline
- PARP-1
- Tissue plasminogen activator
ASJC Scopus subject areas
- Neurology
- Clinical Neurology